伤寒Vi结合疫苗策略与发病率阈值的比较:一项成本效果建模研究
研究用动态年龄结构传播与成本效果模型,从社会视角模拟婴儿EPI常规接种及EPI加5-14岁儿童一次性补种两种策略。结果显示,当年发病例数>50例/10万时EPI常规接种具高度成本效果,>130例/10万时EPI加补种具高度成本效果,阈值对病死率等因素敏感。
要点
- EPI婴儿常规接种在年发病率>50例/10万时具高度成本效果(95%不确定性区间40-75例)。
- EPI加5-14岁儿童补种在年发病率>130例/10万时具高度成本效果(95%不确定性区间50-395例)。
- 发病率阈值对伤寒相关病死率、携带者传播贡献、疫苗特性和国家经济阈值敏感。
核心结论
- 伤寒Vi结合疫苗在中等发病率(年50例/10万)的低收入国家具高度成本效果。
- 结果对病死率敏感,全球接种策略需考虑医疗可及性和抗菌药物耐药等影响伤寒死亡的因素。
研究设计与样本
- 研究使用动态、年龄结构的传播与成本效果模型,从社会视角模拟多种接种策略。
- 模拟10年接种规划,包括经扩大免疫规划(EPI)对婴儿(<1岁)常规接种,以及EPI常规接种加5-14岁学龄儿童一次性补种。
- 基础病例分析假设所有临床有症状伤寒病例病死率为0.5%,采用低收入国家定义(人均国内生产总值1045美元)判定高度成本效果。
- 发病率定义为人群中每年真正临床有症状的人数。
主要发现
- 经EPI常规接种在年发病率>50例/10万(95%不确定性区间40-75例)的场景下具高度成本效果。
- 经EPI加补种在年发病率>130例/10万(95%不确定性区间50-395例)的场景下具高度成本效果。
- 发病率阈值对伤寒相关病死率、携带者传播贡献、疫苗特性和国家特定经济阈值敏感。
关键数值与推荐
- EPI常规接种策略的高度成本效果阈值:年发病率>50例/10万(95%不确定性区间40-75例)。
- EPI加补种策略的高度成本效果阈值:年发病率>130例/10万(95%不确定性区间50-395例)。
- 基础病例假设临床有症状伤寒病死率为0.5%。
- 低收入国家经济阈值定义为人均国内生产总值1045美元。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Typhoid fever remains a major public health problem globally. While new Vi conjugate vaccines hold promise for averting disease, the optimal programmatic delivery remains unclear. We aimed to identify the strategies and associated epidemiologic conditions under which Vi conjugate vaccines would be cost-effective. METHODS: We developed a dynamic, age-structured transmission and cost-effectiveness model that simulated multiple vaccination strategies with a typhoid Vi conjugate vaccine from a societal perspective. We simulated 10-year vaccination programs with (1) routine immunization of infants (aged <1 year) through the Expanded Program on Immunization (EPI) and (2) routine immunization of infants through the EPI plus a 1-time catch-up campaign in school-aged children (aged 5-14 years). In the base case analysis, we assumed a 0.5% case-fatality rate for all cases of clinically symptomatic typhoid fever and defined strategies as highly cost-effective by using the definition of a low-income country (defined as a country with a gross domestic product of $1045 per capita). We defined incidence as the true number of clinically symptomatic people in the population per year. RESULTS: Vi conjugate typhoid vaccines were highly cost-effective when administered by routine immunization activities through the EPI in settings with an annual incidence of >50 cases/100000 (95% uncertainty interval, 40-75 cases) and when administered through the EPI plus a catch-up campaign in settings with an annual incidence of >130 cases/100000 (95% uncertainty interval, 50-395 cases). The incidence threshold was sensitive to the typhoid-related case-fatality rate, carrier contribution to transmission, vaccine characteristics, and country-specific economic threshold for cost-effectiveness. CONCLUSIONS: Typhoid Vi conjugate vaccines would be highly cost-effective in low-income countries in settings of moderate typhoid incidence (50 cases/100000 annually). These results were sensitive to case-fatality rates, underscoring the need to consider factors contributing to typhoid mortality (eg, healthcare access and antimicrobial resistance) in the global vaccination strategy.
引用
- Lo NC, Gupta R, Stanaway JD, et al. Comparison of Strategies and Incidence Thresholds for Vi Conjugate Vaccines Against Typhoid Fever: A Cost-effectiveness Modeling Study. J Infect Dis. 2018. PMID: 29444257. doi:10.1093/infdis/jix598
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。